Furthermore, PIK3CA H1047R mutations, which confer increased sensitivity to alpelisib and fulvestrant, were predominantly seen in TNBC or HER2 + tumors, suggesting an alternative therapeutic opportunity for older BC patients (Additional file 1: Fig. S3B). This evidence concerns the gene ERBB2 and breast cancer.